new cell therapy trial launches for patients with severe covid 19
University of Miami Health System, Miller School of MedicineAn international team of scientists led by Camillo Ricordi, M.D., director of the Diabetes Research Institute and Cell Transplant Center at the University of Miami Miller School of Medicine, has been granted immediate FDA authorization for a 24-patient clinical trial to test the safety and exploratory efficacy of umbilical cord-derived mesenchymal stem cells to block the life-threatening lung inflammation that accompanies severe cases of COVID-19.